Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants

Shujin Wang, Yan Yu, Paul Ryan, Minyan Dang, Cain Clark, Vasileios Kontogi, Jamal Rahmani, Hamed Kord-Varkaneh, Ammar Salehisahlabadi, Andrew S Day, Yong Zhang

Research output: Contribution to journalReview article

Abstract

Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I2=90%). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models.
Original languageEnglish
Article number104585
JournalPharmacological Research
Volume151
Early online date6 Dec 2019
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Aspirin
Hepatocellular Carcinoma
Cohort Studies
Therapeutics
Nonlinear Dynamics
Risk Reduction Behavior
PubMed
MEDLINE
Meta-Analysis
Cardiovascular Diseases
Databases
Research

Keywords

  • Aspirin
  • Hepatocellular carcinoma
  • Liver cancer

ASJC Scopus subject areas

  • Pharmacology

Cite this

Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants. / Wang, Shujin; Yu, Yan; Ryan, Paul; Dang, Minyan; Clark, Cain; Kontogi, Vasileios ; Rahmani, Jamal; Kord-Varkaneh, Hamed; Salehisahlabadi, Ammar ; Day, Andrew S; Zhang, Yong.

In: Pharmacological Research, Vol. 151, 104585, 01.2020.

Research output: Contribution to journalReview article

Wang, Shujin ; Yu, Yan ; Ryan, Paul ; Dang, Minyan ; Clark, Cain ; Kontogi, Vasileios ; Rahmani, Jamal ; Kord-Varkaneh, Hamed ; Salehisahlabadi, Ammar ; Day, Andrew S ; Zhang, Yong. / Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants. In: Pharmacological Research. 2020 ; Vol. 151.
@article{c1df19f7b3264b4e9257105cf03c40a0,
title = "Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants",
abstract = "Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95{\%} CI 0.47-0.75, Pheterogeneity=0.001, I2=90{\%}). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models.",
keywords = "Aspirin, Hepatocellular carcinoma, Liver cancer",
author = "Shujin Wang and Yan Yu and Paul Ryan and Minyan Dang and Cain Clark and Vasileios Kontogi and Jamal Rahmani and Hamed Kord-Varkaneh and Ammar Salehisahlabadi and Day, {Andrew S} and Yong Zhang",
year = "2020",
month = "1",
doi = "10.1016/j.phrs.2019.104585",
language = "English",
volume = "151",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Elsevier",

}

TY - JOUR

T1 - Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants

AU - Wang, Shujin

AU - Yu, Yan

AU - Ryan, Paul

AU - Dang, Minyan

AU - Clark, Cain

AU - Kontogi, Vasileios

AU - Rahmani, Jamal

AU - Kord-Varkaneh, Hamed

AU - Salehisahlabadi, Ammar

AU - Day, Andrew S

AU - Zhang, Yong

PY - 2020/1

Y1 - 2020/1

N2 - Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I2=90%). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models.

AB - Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I2=90%). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models.

KW - Aspirin

KW - Hepatocellular carcinoma

KW - Liver cancer

UR - http://www.scopus.com/inward/record.url?scp=85076294424&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2019.104585

DO - 10.1016/j.phrs.2019.104585

M3 - Review article

VL - 151

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

M1 - 104585

ER -